Gordana Supic1,2, Ruzica Kozomara3,4, Katarina Zeljic5,6, Nebojsa Jovic3,4, Zvonko Magic3,5. 1. Faculty of Medicine, Military Medical Academy, University of Defense, Belgrade, Serbia. gogasupic@sezampro.rs. 2. Institute for Medical Research, Military Medical Academy, Crnotravska 17, Belgrade, 11002, Serbia. gogasupic@sezampro.rs. 3. Faculty of Medicine, Military Medical Academy, University of Defense, Belgrade, Serbia. 4. Clinic for Maxillofacial Surgery, Military Medical Academy, Belgrade, Serbia. 5. Institute for Medical Research, Military Medical Academy, Crnotravska 17, Belgrade, 11002, Serbia. 6. Faculty of Biology, University of Belgrade, Belgrade, Serbia.
Abstract
OBJECTIVES: Although the importance of the epigenetic changes in tumors, including oral squamous cell carcinomas (OSCCs), is now becoming apparent, the mechanisms that trigger or cause aberrant DNA methylation in cancer are still unrevealed. DNA methylation is regulated by a family of enzymes, DNA methyltransferases (DNMTs). DNMT gene expression analysis, as well as genetic polymorphisms, has not been previously evaluated in OSCC. MATERIALS AND METHODS: In 65 OSCC patients, SYBR Green real-time PCR method was assessed for relative quantification of DNMT1, DNMT3A, and DNMT3B mRNAs, normalized to TATA-binding protein (TBP) mRNA. The expression levels of all three genes were dichotomized as high or low, with a twofold change of normalized mRNA expression used as the cutoff value. Polymorphisms in DNMT1 (rs2228612) and DNMT3B (rs406193) were analyzed in 99 OSCCs by TaqMan SNPs genotyping assays. RESULTS: DNMT1, DNMT3A, and DNMT3B were overexpressed in 36.9, 26, and 23 % of the OSCC patients, respectively. DNMT1 overexpression was significantly associated with the overall survival, p = 0.029, and relapse-free survival of OSCC patients, p = 0.003. Patients with DNMT1 overexpression, as an independent prognostic factor, had a 2.385 times higher risk to relapse than those with lower expression. The DNMT1 A201G gene polymorphism was associated with a reduced overall survival in OSCC patients, p = 0.036. CONCLUSIONS: Our results suggest that DNMT1 could play an important role in modulating OSCC patient survival. CLINICAL RELEVANCE: DNMT gene expression could be a potential prognostic marker that might lead to an improvement in diagnosis, prognosis, and prospective use of epigenetic-targeted therapy of OSCC.
OBJECTIVES: Although the importance of the epigenetic changes in tumors, including oral squamous cell carcinomas (OSCCs), is now becoming apparent, the mechanisms that trigger or cause aberrant DNA methylation in cancer are still unrevealed. DNA methylation is regulated by a family of enzymes, DNA methyltransferases (DNMTs). DNMT gene expression analysis, as well as genetic polymorphisms, has not been previously evaluated in OSCC. MATERIALS AND METHODS: In 65 OSCC patients, SYBR Green real-time PCR method was assessed for relative quantification of DNMT1, DNMT3A, and DNMT3B mRNAs, normalized to TATA-binding protein (TBP) mRNA. The expression levels of all three genes were dichotomized as high or low, with a twofold change of normalized mRNA expression used as the cutoff value. Polymorphisms in DNMT1 (rs2228612) and DNMT3B (rs406193) were analyzed in 99 OSCCs by TaqMan SNPs genotyping assays. RESULTS:DNMT1, DNMT3A, and DNMT3B were overexpressed in 36.9, 26, and 23 % of the OSCC patients, respectively. DNMT1 overexpression was significantly associated with the overall survival, p = 0.029, and relapse-free survival of OSCC patients, p = 0.003. Patients with DNMT1 overexpression, as an independent prognostic factor, had a 2.385 times higher risk to relapse than those with lower expression. The DNMT1A201G gene polymorphism was associated with a reduced overall survival in OSCC patients, p = 0.036. CONCLUSIONS: Our results suggest that DNMT1 could play an important role in modulating OSCC patient survival. CLINICAL RELEVANCE: DNMT gene expression could be a potential prognostic marker that might lead to an improvement in diagnosis, prognosis, and prospective use of epigenetic-targeted therapy of OSCC.
Authors: Gerda Egger; Shinwu Jeong; Sonia G Escobar; Connie C Cortez; Tony W H Li; Yoshimasa Saito; Christine B Yoo; Peter A Jones; Gangning Liang Journal: Proc Natl Acad Sci U S A Date: 2006-09-08 Impact factor: 11.205
Authors: Luo Wang; Marivonne Rodriguez; Edward S Kim; Yunling Xu; Neby Bekele; Adel K El-Naggar; Waun Ki Hong; Li Mao; Yun W Oh Journal: Int J Oncol Date: 2004-10 Impact factor: 5.650
Authors: Horacio Cardenas; Fang Fang; Guanglong Jiang; Susan M Perkins; Chi Zhang; Robert E Emerson; George Hutchins; Harold N Keer; Yunlong Liu; Daniela Matei; Kenneth Nephew Journal: Epigenetics Date: 2020-12-08 Impact factor: 4.528
Authors: Chandrika J Piyathilake; Suguna Badiga; Samuel G Borak; Janaka Weragoda; Sejong Bae; Roland Matthews; Walter C Bell; Edward E Partridge Journal: Int J Womens Health Date: 2017-06-08
Authors: Nicole L Michmerhuizen; Megan L Ludwig; Andrew C Birkeland; Sai Nimmagadda; Jingyi Zhai; Jiayu Wang; Brittany M Jewell; Dylan Genouw; Lindsay Remer; Daniel Kim; Susan K Foltin; Apurva Bhangale; Aditi Kulkarni; Carol R Bradford; Paul L Swiecicki; Thomas E Carey; Hui Jiang; J Chad Brenner Journal: Head Neck Date: 2022-02-27 Impact factor: 3.821